Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07110636Recruiting
Blood test for infection in immunocompromised adults
This trial tests a blood test that looks for infection by analyzing tiny bits of DNA from microbes. It may help find infections faster in people with weakened immune systems, such as transplant recipients or those with blood cancers.
San Francisco, CaliforniaAges 18 years+ - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT07113691RecruitingPhase 1
Experimental drug plus radiation and immunotherapy for lung cancer
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
New Haven, ConnecticutAges 18 years+ - NCT07111273Recruiting
Predicting relapse in ulcerative colitis with early stool tests
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
Jinan, ShandongAges 18–75 - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07101432RecruitingPhase 1
Radiation plus engineered NK cells for advanced head and neck cancer
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Houston, TexasAges 18 years+ - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07087314RecruitingPhase 2
Study of an injection for nephrotic syndrome in children
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
Hangzhou, ZhejiangAges 6–18 - NCT07092670Recruiting
Melanoma treatment after surgery and its effect on fertility
This study looks at how adjuvant therapy (treatment after surgery) affects fertility in women under 40 who have had their melanoma completely removed. It will help doctors understand and manage the impact on future childbearing.
BariAges Up to 40 years - NCT06972602RecruitingEarly Phase 1
High-dose topotecan for retinoblastoma with vitreous seeds
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
Shanghai, ChinaAges 1–12 - NCT06869265RecruitingPhase 2
Thiotepa added to standard chemo before a stem cell transplant for older adults with high-risk AML
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
Beijing, Beijing MunicipalityAges 55–70 - NCT06978894Recruiting
Using speech to detect psychosis relapse early
This study tests whether changes in your speech patterns can help predict a psychotic relapse before it happens. If you're in an early psychosis program, you may help develop a tool that could warn you and your care team early.
London, OntarioAges 16 years+ - NCT06980155RecruitingEarly Phase 1
Personalized vaccine with or without toripalimab to prevent AML relapse
This trial tests a personalized cancer vaccine, alone or with an immunotherapy drug called toripalimab, to help keep acute myeloid leukemia (AML) in remission. It is for people who have finished initial treatment, are in remission, but still have some leukemia cells remaining (MRD positive) and have a specific NPM1 gene mutation.
ShanghaiAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT03401879Recruiting
Study eye blood-flow changes in multiple sclerosis
This study measures how blood flow in the eye changes in people with relapsing-remitting multiple sclerosis (RRMS) who previously had optic neuritis. The goal is to understand eye/brain blood-flow signals and how they may relate to MS.
Vienna, AustriaAges 18 years+ - NCT06718244RecruitingPhase 2
CNCT19 for B-ALL with minimal remaining cancer after first remission
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT07060274Recruiting
How fast does the halo sign vanish after steroids in GCA?
This trial is for people newly diagnosed with giant cell arteritis (GCA) who have a 'halo' sign on their temporal artery ultrasound. It will study how quickly the halo disappears after starting steroid treatment, helping doctors understand the best way to use steroids for this condition.
Le Mans, SartheAges 50 years+ - NCT07058298RecruitingEarly Phase 1
GC012F injection for hard-to-treat myasthenia gravis
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
Wuhan, HubeiAges 18–75 - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07052916Recruiting
Music therapy for thinking and memory after blood cancer
This study tests whether music therapy can help blood cancer survivors who have trouble with thinking, memory, or concentration. It is for people with lymphoma, leukemia, or myeloma whose disease is stable or in remission.
Basking Ridge, New JerseyAges 18 years+ - NCT07052175Recruiting
Preventing relapse in behavioral disorders with a smartphone app
This study tests whether a smartphone app can help prevent relapse in people with behavioral disorders. If you speak Spanish, have a smartphone, and are willing to use the app, you may be able to join.
Ciempozuelos, MadridAges 18–90 - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07040982RecruitingPhase 1
Asciminib after cell therapy for Ph+ ALL
This trial tests the drug asciminib after a stem cell transplant or CAR T-cell therapy for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) to help prevent the cancer from coming back.
Duarte, CaliforniaAges 18 years+
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,718 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.